Skip to Content

Gazyva Side Effects

Generic Name: obinutuzumab

Note: This document contains side effect information about obinutuzumab. Some of the dosage forms listed on this page may not apply to the brand name Gazyva.

For the Consumer

Applies to obinutuzumab: intravenous solution

Along with its needed effects, obinutuzumab (the active ingredient contained in Gazyva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking obinutuzumab:

More common
  • Back pain
  • black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • chest tightness
  • chills
  • cough
  • fever
  • flushing
  • headache
  • hoarseness
  • lower back or side pain
  • nausea
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • sore throat
  • trouble breathing
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting
Less common
  • Joint pain, stiffness, or swelling
  • stomach pain
  • swelling of the feet or lower legs
Incidence not known
  • Blurred vision
  • confusion
  • dark urine
  • dizziness
  • drowsiness
  • general tiredness and weakness
  • light-colored stools
  • seizures
  • upper right abdominal or stomach pain
  • yellow eyes and skin

Some side effects of obinutuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known
  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to obinutuzumab: intravenous solution


Common (1% to 10%): Hypertension, cardiac failure
Frequency not reported: Worsening of preexisting cardiac conditions with fatalities, atrial fibrillation[Ref]


Very common (10% or more): Neutropenia (41%), thrombocytopenia (15%), anemia (12%)
Common (1% to 10%): Leukopenia, lymph node pain[Ref]


Very common (10% or more): AST (SGOT) increased (28%), ALT (SGPT) increased (25%)[Ref]


Very common (10% or more): Hypophosphatemia (36%), hypoalbuminemia (33%), hypoproteinemia (32%), hypocalcemia (32%), hypocalcemia (32%), hyperuricemia (28%), hyponatremia (26%), hyperkalemia (23%), hypernatremia (16%) alkaline phosphatase increased (16%), decreased appetite (14%)
Common (1% to 10%): Tumor lysis syndrome, hyperuricemia[Ref]


Common (1% to 10%): Arthralgia, back pain, musculoskeletal chest pain, pain in extremity, bone pain[Ref]

Nervous system

Very common (10% or more): Headache (18%), asthenia
Frequency not reported: Progressive multifocal leukoencephalopathy (PML)[Ref]


Very common (10% or more): Pyrexia (18%)[Ref]


Very common (10% or more): Creatinine increased (30%)[Ref]


Very common (10% or more): Cough (26%), pneumonia (14%), sinusitis (12%), upper respiratory tract infection
Common (1% to 10%): Rhinitis, pharyngitis, nasopharyngitis, lung infection, nasal congestion, rhinorrhea, lung infection[Ref]


Very common (10% or more): Positive test for anti-obinutuzumab (the active ingredient contained in Gazyva) antibodies (13%)
Common (1% to 10%): Infection (9%)
Frequency not reported: Hepatitis B reactivation, immunogenicity[Ref]


Very common (10% or more): Alopecia (13%)
Common (1% to 10%): Pruritus, night sweats, eczema[Ref]


Very common (10% or more): Infusion related reactions (69%)[Ref]


Common (1% to 10%): Ocular hyperemia[Ref]


Common (1% to 10%): Urinary tract infection, urinary incontinence, dysuria[Ref]


Common (1% to 10%): Squamous cell carcinoma of the skin[Ref]


Very common (10% or more): Constipation (19%), diarrhea (10%)
Common (1% to 10%): Oral herpes, dyspepsia, colitis, hemorrhoids[Ref]


Frequency not reported: This drug can cause serious infusion reactions. See Warnings.[Ref]


1. "Product Information. Gazyva (obinutuzumab)." Genentech, South San Francisco, CA.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Some side effects of Gazyva may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.